Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.

Tuberculosis (Edinburgh, Scotland) - 1 May 2017

Maltempe Flaviane Granero, Caleffi-Ferracioli Katiany Rizzieri, do Amaral Renata Claro Ribeiro, de Oliveira Demitto Fernanda, Siqueira Vera Lúcia Dias, de Lima Scodro Regiane Bertin, Hirata Mário Hiroyuki, Pavan Fernando Rogério, Cardoso Rosilene Fressatti

Abstract excerpt

BACKGROUND: Linezolid (LZD) is not commonly used for treating tuberculosis (TB), but in some patients with drug-resistant TB it is being used. However, the in vitro LZD activity, in combination with rifampicin (RIF) against Mycobacterium tuberculosis has not been fully elucidated. AIMS: The aim of this study was to evaluate the in vitro activity of RIF/LZD combination against M. tuberculosis clinical isolates....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Drug Resistance, Multiple, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Drug Therapy, Combination

Share to Linezolid

Share to Microbial Viability

Share to Mycobacterium tuberculosis

Share to Rifampin

Source

Identifiers

PMID: 28454646
DOI: 10.1016/j.tube.2017.02.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.PMID 28454646Read ↗

Mycobacterium Tuberculosis: Drug Resistance and Future PerspectivesSemantic proximity Read ↗

Totally drug-resistant tuberculosis and adjunct therapies.Semantic proximity Read ↗

Mechanisms of drug resistance in mycobacterium tuberculosisSemantic proximity Read ↗

Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.Semantic proximity Read ↗

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity Read ↗

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisSemantic proximity Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

In vitro antimycobacterial activity of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione: a new chemical entity against Mycobacterium tuberculosis.Semantic proximity Read ↗

In vitro toxic action potential of anti tuberculosis drugs and their combinations.Semantic proximity Read ↗

Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.Semantic proximity Read ↗

Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.Semantic proximity Read ↗

An interesting case of rifampicin-dependent/-enhanced multidrug-resistant tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.